This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Muscular Dystrophy, Facioscapulohumeral
Information about Muscular Dystrophy, Facioscapulohumeral: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Muscular Dystrophy, Facioscapulohumeral
Most recent studies have shown that Muscular Dystrophy, Facioscapulohumeral shares some biological mechanisms with atrophy, becker-muscular-dystrophy, dystrophy, embryonic-mosaic, facial-paresis, facioscapulohumeral-muscular-dystrophy-1a, muscle-weakness, muscular-atrophy, muscular-dystrophies-limb-girdle, muscular-dystrophy, muscular-dystrophy-duchenne, myopathy, myositis, myotonic-dystrophy, neuromuscular-diseases, pain, spinal-muscular-atrophy, weakness.
Among the many pathways, these few ones have gauged particular interests from scientists studying Muscular Dystrophy, Facioscapulohumeral, and have been seen in publications frequently: Angiogenesis, Cell Cycle, Cell Death, Chromatin Organization, Dna Methylation, Gene Conversion, Gene Silencing, Histone Modification, Interphase, Localization, Methylation, Muscle Atrophy, Myoblast Differentiation, Myoblast Proliferation, Pathogenesis, Reflex, Regeneration, Response To Oxidative Stress, Rna Interference, Transport
Quite a number of genes have been found to play important roles in Muscular Dystrophy, Facioscapulohumeral, such as ALPP, ASRGL1, BEST1, BRD2, CCL27, CHKA, CHKB, DMD, DMPK, DUX4, FRG1, FRG2, MYOD1, PDLIM3, PITX1, PRPF6, SLC25A4, SLPI, SOD1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.